Pharmaceuticals

HUTCHMED

Hengrui Medicine Announces Phase II Results for Fanregratinib in FGFR2-Altered Biliary Tract Cancer: 42.5% ORR and NMPA Priority Review

 Hutchison MediPharma to Present Preclinical Data on HMPL-A580 at AACR Annual Meeting

Huayuan Securities Maintains Buy Rating for Hutchmed, Predicts Revenue for 2026-2028

HUTCHMED Announces Latest Progress on TAZVERIK® Licensing in China

Chi-Med Reports Revenue Decline and Significant Profit Increase in 2025

CLSA Adjusts HUTCHMED's 2026 Performance Forecast and Target Price

HUTCHMED released FY2025 Q3 earnings on March 5, 2026 (BJT) with actual revenue of HKD 1.054 B and EPS of HKD 0.0007

HUTCHMED released FY2025 9 Months earnings on March 5, 2026 (BJT), actual revenue HKD 3.224 B, actual EPS HKD 4.0643

HUTCHMED released FY2025 earnings on March 5 After-Market (BJT), actual revenue HKD 4.277 B (forecast HKD 4.544 B), actual EPS HKD 4.0548 (forecast HKD 3.8377)

HUTCHMED released FY2025 Q4 earnings on March 5 After-Market (BJT), actual revenue HKD 1.054 B, actual EPS HKD 0.0007

HUTCHMED to Release FY2025 Annual Earnings on March 5, 2026 After-Market (BJT), Forecast Revenue HKD 4.555 B, EPS HKD 3.8467

Elium Pharmaceutical's Multiple Drugs Included in the New National Medical Insurance Drug Directory

Hutchmed Announces SACHI Phase III Lung Cancer Trial Results Published in The Lancet, Shares Fall

Hopscotch Therapeutics Announces Successful SACHI Trial Results

HUTCHMED stock price falls below 200-day moving average

Hopewell sovleplenib Phase III Trial Results Positive

HUTCHMED Initiates Phase III Study for Pancreatic Cancer Treatment

Hopson Medical Launches Phase III Clinical Trial for Suralivimab and Camrelizumab Combination Therapy for Metastatic Pancreatic Cancer

Hopewell Healthcare's Savolitinib New Drug Application Accepted by China's National Drug Regulatory Authority

Chi-Med's MET inhibitor savolitinib NDA accepted and granted priority review by NMPA

PASHUN INT'L

JIAODA WITHUB

HJ SCIENCE-B

SCIENTECH

PRODUCTIVE TECH

CH FRONTIER TEC

PLATT NERA

CHI HO DEV

WECON HOLDINGS

NEW GONOW RV

00013

HUTCHMED reported strong Phase II data for fanregratinib in FGFR2-positive cholangiocarcinoma, showing a 42.5% response rate. China's NMPA granted priority review to its New Drug Application. Approval could strengthen HUTCHMED's oncology portfolio. The stock currently holds a 'Hold' rating with a HK$21.30 target.

Tip Ranks

Hutchmed China

HUTCHMED’s Fanregratinib Delivers Strong Phase II Data in FGFR2-Positive Cholangiocarcinoma

HUTCHMED announced Phase II results for fanregratinib in FGFR2-altered intrahepatic cholangiocarcinoma, showing a 42.5% response rate with rapid onset and sustained disease control. The China NMPA accepted the NDA in December 2025, granting priority review. Safety profiles were consistent with selective FGFR inhibitors, with no treatment-related deaths reported.

PUBT

HUTCHMED says Phase II fanregratinib trial in FGFR2-altered bile duct cancer posts 42.5% response rate

HUTCHMED presented Phase III ESLIM-02 data for sovleplenib in warm antibody autoimmune hemolytic anemia (wAIHA) at EHA 2026. The study showed rapid, durable hemoglobin responses and a favorable safety profile versus placebo. This supports the NMPA's acceptance of the New Drug Application for priority review. Sovleplenib significantly reduced rescue therapy needs and transfusions, addressing unmet needs in wAIHA treatment.

GlobeNewswire

HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress

HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting | HCM Stock News

StockTitan

HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting | HCM Stock News

520690

588130

159849

516930

Immunitas Therapeutics presented Phase 1/2a data for its novel immunotherapy IMT-009 at the AACR Annual Meeting 2026. The data showed IMT-009 was well tolerated and demonstrated early anti-tumor activity in heavily pretreated patients, particularly in microsatellite stable colorectal cancer. The findings suggest potential biomarkers for patient selection and support further evaluation of IMT-009 as both a monotherapy and in combination with fruquintinib. The study highlights IMT-009's promise in addressing unmet needs in difficult-to-treat cancers.

prnewswire

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

First Trust NYSE Arca Biotech Index Fd

Minsheng Royal CSI Biotechnology Theme ETF

15:00 ETImmunitas Presents Phase 1/2a Data Highlighting Anti-Tumor Activity of Novel Immunotherapy IMT-009 at AACR 2026 Annual Meeting

HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China | HCM Stock News

HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China | HCM Stock News

HUTCHMED(00013.HK)

HUTCHMED’s Fanregratinib Delivers Strong Phase II Data in FGFR2-Positive Cholangiocarcinoma

HUTCHMED says Phase II fanregratinib trial in FGFR2-altered bile duct cancer posts 42.5% response rate

HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress

HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting | HCM Stock News

15:00 ETImmunitas Presents Phase 1/2a Data Highlighting Anti-Tumor Activity of Novel Immunotherapy IMT-009 at AACR 2026 Annual Meeting

HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China | HCM Stock News